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Surface activityReasonable suspicion has accumulated that inhaled nano-scale particulate matter inﬂuences the biophysical
function of the pulmonary surfactant system. Hence, it is evident to provide novel insights into the extent and
mechanisms of nanoparticle–surfactant interactions in order to facilitate the fabrication of safe nanomedicines
suitable for pulmonary applications.
Negatively- and positively-charged poly(styrene) nanoparticles (diameters of ~100 nm) served as model
carriers. Nanoparticles were incubated with several synthetic and naturally-derived pulmonary surfactants to
characterize the sensitivity of each preparation to biophysical inactivation. Changes in surface properties
(i.e. adsorption and dynamic surface tension behavior) were monitored in a pulsating bubble surfactometer.
Both nanoparticle formulations revealed a dose-dependent inﬂuence on the biophysical behavior of all investi-
gated pulmonary surfactants. However, the surfactant sensitivity towards inhibition depended on both the car-
rier type, where negatively-charged nanoparticles showed increased inactivation potency compared to their
positively-charged counterparts, and surfactant composition. Among the surfactants tested, synthetic mixtures
(i.e. phospholipids, phospholipids supplemented with surfactant protein B, and Venticute®) were more suscep-
tible to surface-activity inhibition as themore complex naturally-derived preparations (i.e. Alveofact® and large
surfactant aggregates isolated from rabbit bronchoalveolar lavage ﬂuid).
Overall, nanoparticle characteristics and surfactant constitution both inﬂuence the extent of biophysical inhibi-
tion of pulmonary surfactants.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Nanomedicine represents a valuable drug delivery platform for the
treatment of lung disorders following inhalation [1]. Among the numer-
ous potential carrier systems, polymeric nanoparticles (NP) enablebronchoalveolar lavage ﬂuid;
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ights reserved.controlled drug release and targeting properties and thus, optimized
the pharmacokinetic [2–4] and dynamic [5,6] proﬁle of the encapsulat-
ed drug within the respiratory tract. However, the safety assessment of
nano-scale drug delivery vehicles is currently a subject of intense
research [7,8], especially after pulmonary challenge [9–11]. So far,
evidence has accumulated that physicochemical (i.e. size and surface
charge) and material (i.e. degradability) properties of polymeric NP as
well as their concentration at the target site determine inﬂammatory
responses within the lung [12,13]. Another toxicological aspect of
lung-delivered NP arises from their direct interaction with the pulmo-
nary surfactant system, a research ﬁeld where only scant information
is available [14–18].
Pulmonary surfactant, a mixture of ~90% of lipids (mainly phospho-
lipids (PL)) and ~10% of proteins (mainly surfactant associated proteins
(SP)), that covers the alveolar region of the lung prevents collapse of the
alveoli by a drastic reduction in surface tension and concurrent promo-
tion of the gaseous exchange [19,20]. A complex interaction between PL
and SP enables the formation of ﬁlms highly enrichedwith PL at the air–
water interface [21]. During surface ﬁlm compression (expiration), SP
aid to purify themonolayer by removing the less surface active compo-
nents into the bulk phase [22]. Upon inspiration (expansion of the
alveolar surface area), SP facilitate a rapid re-entry and re-spreading of
surfactant compounds located in the bulk phase.
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have severe outcome [15]. Pulmonary surfactant function can be
dramatically inﬂuenced by particulate matter as demonstrated for
inorganic (i.e. gold [23,24], titanium dioxide [25], and hydroxyapatite
[26]), composite (i.e. AmorSil [27,28]) and polymeric (i.e. gelatin
[29–31], poly(n-butyl cyanoacrylate) [32], poly(styrene) [25,33],
poly(lactide-co-glycolide) [33] and EUDRAGIT® E100 [33]) NP. Howev-
er, it remains challenging to provide deﬁnite conclusions on the extent
of surfactant inhibition by NP from the existing in vitro studies, due
to the employment and combination of diverse NP and pulmonary sur-
factant (i.e. synthetic [23,24,27–32] and naturally-derived [24–26,33])
preparations and experimental setups (i.e. ﬁlm balance [24,26–32],
captive- [23] and pulsating bubble surfactometer (PBS) [25,33]).
Therefore, this study aimed at characterizing biophysical interac-
tions between lung surfactants and two standardized polymeric NP
formulations to provide systematic insights into the NP-surfactant in-
terplay. NP were characterized for size, size distribution, morphology,
and ζ-potential by dynamic light scattering, transmission electron
microscopy, and laser Doppler anemometry. Next, the surface proper-
ties of the synthetic and naturally-derived pulmonary surfactants with
or without polymeric NPwere examined bymonitoring the equilibrium
(γads) and dynamic (γmin) surface tension behavior in a PBS. Finally, the
extent of biophysical inhibition was analyzed from the obtained dose-
effect curves (e.g. half maximal inhibitory NP concentration value
(IC50)). We hypothesized that the sensitivity of the respective pulmo-
nary surfactant preparation to biophysical inhibition by polymeric NP
is signiﬁcantly affected by both the NP characteristics and surfactant
composition.
2. Materials and methods
2.1. Materials
Negatively- and positively-charged poly(styrene) NP with nominal
diameters of 100 nm (PS100− and PS100+) were purchased
from Polysciences (Eppelheim, Germany) and Invitrogen (Darmstadt,
Germany), respectively. Alveofact® was obtained from Lyomark
(Oberhaching, Germany). Venticute® was from Nycomed (Konstanz,
Germany). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (so-
dium salt) (POPG) and palmitic acid (PA) were acquired from
Sigma-Aldrich (Steinheim, Germany). All other chemicals and
solvents used in this study were of the highest analytical grade
commercially available.
2.2. Methods
2.2.1. Preparation and characterization of NP
PS100− and PS100+ were puriﬁed by dialysis against distilled
water (MWCO: 50,000 Da, Spectra/Por® 6, Breda, Netherlands) to
remove additives (i.e. surface active stabilizers and preservatives). The
actual NP concentration in suspension was assessed gravimetrically
after lyophilization (ALPHA 1–4 LSC, Christ, Osterode, Germany).
The particle size (i.e. hydrodynamic diameter) and size distribution
(i.e. polydispersity index (PDI)) of NP were measured by dynamic
light scattering (DLS), and their ζ-potential was determined by laser
Doppler anemometry (LDA) (Zetasizer NanoZS/ZEN3600, Malvern
Instruments, Herrenberg, Germany). The morphology of NP was inves-
tigated by transmission electron microscopy (TEM) (JEM-3010 TEM,
JEOL, Eching, Germany).
2.2.2. Isolation of SP-B
SP-B was isolated from Alveofact® by means of LH60-
chromatography as described previously [34–36]. The purity amounted
to 95% as assessed by SDS-PAGE [36,37]. The concentration of the
puriﬁed SP-B was determined using a protein assay [38].2.2.3. Bronchoalveolar lavage (BAL) and isolation of large surfactant aggre-
gates (LSA) from BAL ﬂuid (BALF)
Male rabbits (body weight: 2.5–3.5 kg) were sacriﬁced by intrave-
nous application of a lethal dose of pentobarbital/ketamine. A catheter
was immediately placed into the trachea and lungs were lavaged
three times with 50 ml of ice-cold isotonic saline. After ﬁltration
through sterile gauze and sedimentation of cells (300 g, 15 min, 4 °C),
supernatants were pooled and stored at−80 °C until further process-
ing. LSA were isolated from BALF by high speed centrifugation
(48,000 g, 60 min, 4 °C; Sorvall centrifuge (SS34 rotor), DuPont, Bad
Homburg, Germany) [39,40].2.2.4. Determination of PL content
Lipids were extracted from the surfactant preparations according to
Bligh and Dyer [41]. PL were quantiﬁed by means of a colorimetric
phosphorus assay [42].2.2.5. Preparation of surfactant materials for biophysical studies
A synthetic PL mixture (PLM) was prepared by dissolving DPPC
(69.0 wt.%), POPG (22.0 wt.%) and PA (9.0 wt.%) [43] in a mixture of
chloroform/methanol (2/1 (v/v)) followed by sample drying under
nitrogen gas. Supplementation of the PLM with SP-B (PLM-B) was
achieved by adding the hydrophobic SP dissolved in chloroform/meth-
anol to the organic PLM stock solution before drying [36]. Venticute®
and Alveofact® were supplied as lyophilized powders, while LSA was
isolated by high-speed centrifugation from rabbit BALF. All surfactant
preparations were adjusted to a ﬁnal PL concentration of 50 mg/ml.2.2.6. Biophysical studies
Surface activity of samples was assessed by the oscillating bubble
technique using a PBS (Electronetics Corp., Amherst, USA) as previously
described [33,44]. The technique provided read-outs of the surface ten-
sion after ﬁlm adsorption (γads, static measurement) and at aminimum
bubble radius during ﬁlm oscillation (γmin, dynamic measurement).
Measurements of the prepared surfactants were performed at a
constant PL concentration of 2 mg/ml in isotonic NaCl solution contain-
ing 2 mM Ca2+ at 37 °C (samples were fabricated from pulmonary
surfactant stock suspensions). The concentration of polymeric NP
(cNP) added (from polymeric NP stock suspensions) to the surfactant
preparation was adjusted between 0.2 and 5 mg/ml prior to the surface
activity experiments. Brieﬂy, after a 30 min incubation period at 37 °C
(without shaking), samples of 30 μl were transferred to the disposable
sample chamber, and adsorption rate was measured. Therefore, a
bubble of minimal radius (0.4 mm) was created and while maintaining
the bubble at that minimal size without pulsation, pressure difference
across the air/liquid interface was monitored. Next pulsation was
started by sinusoidally oscillating the bubble radius between 0.4 and
0.55 mm. The cycling rate was set to 20 cycles/min. The pressure differ-
ences across the air/liquid interface were recorded continuously. Using
the Young–Laplace equation, the surface tension was calculated with a
microprocessor. γads and γmin values were read after 12 and 300 s,
respectively. Dose-effect curve characteristics were calculated using a
sigmoidal dose-response function (GraphPad Prism 5, GraphPad Soft-
ware, La Jolla, USA).2.2.7. Statistics
All measurements were carried out in triplicate and values are
presented as the mean ± S.D. unless otherwise noted. To identify
statistically signiﬁcant differences, one-way ANOVA with Bonferroni's
post t-test analysis was performed (SigmaStat 3.5, STATCON,
Witzenhausen, Germany). Probability values of p b 0.05 were
considered signiﬁcant.
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3.1. NP characteristics
NP formulations (PS100− and PS100+) were of spherical shape,
had a mean size of ~100 nm with narrow size distributions (Fig. 1A, B,
Table 1). The corresponding ζ-potential of PS100− was ~−46 mV
and for PS100+ a value of ~60 mV was obtained (Fig. 1C, Table 1).
The equilibrium surface tension and dynamic surface tension behav-
ior under pulsation were investigated for the solvent (i.e. isotonic NaCl
solution containing 2 mM Ca2+) and both NP formulations at a cNP of
2 mg/ml using the PBS technique (Table 1). The solvent alone revealed
no signs of surface activity. The γads and γmin value remained at
72.1 ± 2.2 and 70.5 ± 2.7 mN/m (mean ± S.D., n = 7), respectively.
Similar to the pure solvent, both NP formulations displayed any
substantial surface activity. Nodecrease in surface tensionwas observed
during the adsorption phase and under bubble pulsation for PS100−
and PS100 + .
3.2. Characteristics of surfactant preparations
Based on origin and composition, available surfactants are generally
divided into simpliﬁed synthetic and more complex naturally-derived
surfactants from animal sources [45]. Five pulmonary surfactant
preparations with diverse biochemical composition and biophysical
characteristics were employed in the current study (Table 2), among
them synthetic (i.e. PLM, PLM-B, and Venticute®) as well as naturally-
derived (i.e. Alveofact® and LSA) surfactants.
The PLMwas prepared according to Tanaka et al. [43], comprising a
phospatidylcholine (DPPC), a phosphatidylglycerol (POPG), and a fatty
acid (PA). PLM-B was prepared by supplementing the PLM with SP-B.
The synthetic surfactant Venticute® was composed of DPPC, POPG, PA,
CaCl2, and recombinant SP-C (rSP-C) [48]. The naturally-derived pulmo-
nary surfactant Alveofact® was isolated from bovine BALF by chloro-
form/methanol extraction. Hence, Alveofact® contains all of the PL of
natural lung surfactant, including mainly phosphatidylcholines and
phosphatidylglycerols, both hydrophobic SP, and a minor amount of
diverse lipids (e.g. fatty acids and cholesterol) [45–47,50]. LSA, which
were obtained from rabbit BALF by differential centrifugation, represent
the predominant surfactant fraction of natural lung surfactant, contain-
ing hydrophilic (e.g. SP-A) and a high content of hydrophobic (e.g. PL
and SP-B and SP-C) constituents [39,49].
The surface properties of the diverse pulmonary surfactant prepara-
tions displayed rapid adsorption (γads b 30 mN/m (n = 10)) and near-
zero minimal surface tension values (γmin ≤ 3 mN/m (n = 10))
when tested in the PBS at a PL concentration of 2 mg/ml (Table 2).
Among the diverse formulations, only the PLM revealed signiﬁcantly
reduced surface activity during adsorption and bubble oscillation
(γads = 54.0 ± 8.9 mN/m (mean ± S.D. (n = 10);γmin = 17.3 ± 3.9 -
mN/m (mean ± S.D. (n = 10)).
3.3. Biophysical inhibition of surfactant preparations by polymeric NP
The diverse surfactant preparations were investigated for biophysi-
cal activity (i.e. adsorption facilities (γads) (Fig. 2) and minimal surface
tension behavior under bubble pulsation (γmin) (Figs. 3 and 4,
Table 3)) in the presence of PS100− and PS100+, respectively. There-
fore, surfactant preparations (2 mg PL/ml) were incubated with
increasing cNP ranging from 0.2 to 5.0 mg/ml.Fig. 1. Representative TEM images of PS100− (A) and PS100+ (B). The insets in (A) and
(B) reveal typical particle size distribution curves fromDLS analysis. The solid lines repre-
sent the particle size density distribution, and the dashed lines represent the cumulative
particle size distribution. Typical ζ-potential distribution curves for the NP formulations
from LDA analysis are illustrated in (C).
Table 1
Physicochemical characteristics of polymeric NP formulations.
Formulation Size/nm PDI ζ-Potential/
mV
γadsa / mN/
m
γmina / mN/
m
PS100− 96.8 ± 0.3 0.022 ± 0.010 −46.3 ± 3.3 68.8 ± 1.4 65.1 ± 0.6
PS100+ 94.8 ± 1.1 0.019 ± 0.006 59.0 ± 2.5 70.9 ± 2.1 69.5 ± 1.6
Values are presented as the mean ± S.D. (n ≥ 3).
a As determined by the PBS technique at a cNP of 2 mg/ml.
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adversely affected by addition of a “low” dose of PS100− and
PS100+ (i.e. 0.5 mg/ml) (Fig. 2). Higher concentrations of polymeric
NP (i.e. 5.0 mg/ml) led to signiﬁcantly decreased adsorption properties
for all surfactants tested (except LSA incubated with PS100+), howev-
er, at considerably different ﬁnal γads values. Both naturally-derived
pulmonary surfactants (i.e. Alveofact® and LSA) exhibited signiﬁcantly
lower sensitivity to changes in γads values upon NP addition than the
synthetic surfactantmixtures. LSA revealed the signiﬁcantly highest sta-
bility, when tested in the presence of PS100− or PS100+ (5 mg/ml).
Moreover, adsorption studies disclosed elevated surfactant sensitivity
to PS100− compared to PS100+.
The inﬂuence of PS100− and PS100+ on the diverse pulmonary
surfactant preparations was also obvious during measurements of
γmin (Fig. 3). Under bubble oscillation NP caused a dose-dependent ef-
fect on γmin of all surfactants, with similar characteristics regarding
curve progression, yet at substantially different sensitivities. Following
γmin values, which remained indistinguishable from the control values
displayed in Table 2 for “low” NP concentrations (i.e. b0.7 mg/ml), a
sudden elevation of γmin was observed upon contact with higher
doses of polymeric NP, ending up in stable minimum surface tension
plateaus. Dose-effect curve characteristics were then calculated using
a sigmoidal dose-response function (Fig. 4, Table 3). Here, IC50 values
ranging from 0.9 ± 0.2 to 1.7 ± 0.3 mg/ml (mean ± S.D., n ≥ 4) and
1.0 ± 0.1 to 2.1 ± 0.1 mg/ml (mean ± S.D., n ≥ 4) (Fig. 4A), γmin
plateau values ranging from 55.8 ± 6.7 to 12.7 ± 1.7 mN/m
(mean ± S.D., n ≥ 4) and 46.1 ± 5.0 to 7.8 ± 1.7 mN/m (mean ±
S.D.,n ≥ 4) (Fig. 4B) andNP concentrations required to increase theγmin
to values of ≥ 5 mN/m ranging from 0.7 ± 0.1 to 1.4 ± 0.1 mg/ml
(mean ±S.D., n ≥ 4) and 0.9 ± 0.2 to 2.7 ± 0.8 mg/ml (mean ± S.D.,
n ≥ 4) (Table 3) were determined for the diverse pulmonary surfactant
preparations incubated with PS100− and PS100+, respectively.
The overall stability of the pulmonary surfactant preparations
towards minimum surface tension changes by polymeric NP during
bubble pulsation agreed well with observations from adsorption exper-
iments (Fig. 2). Among the synthetic surfactants, PLM-B demonstrated a
lower sensitivity to inhibition than Venticute® (i.e. PLM supplemented
with rSP-C). Other than for the synthetic surfactants, signiﬁcantly
increased NP doses were necessary to inhibit the naturally-derived
pulmonary surfactants (i.e. Alveofact® and LSA). LSA revealed the con-
siderably highest stability of all tested surfactant preparations. ApartTable 2
Biochemical composition and biophysical characteristics of the employed pulmonary surfactan
Preparation PL (wt.%) SP (wt.%)
PLM DPPC (69.0)
POPG (22.0)
–
PLM-B DPPC (69.0)
POPG (22.0)
SP-B (1.8)
Venticute® DPPC (63.4)a
POPG (27.8)a
rSP-C (1.8)a
Alveofact® diverse PL (~90.0)a SP-B, SP-C (~2.0)a
LSA diverse PL (~90.0)a SP-A, SP-B, SP-C (~5.0)a
a Values obtained from the literature [39,45–50].
b Values are presented as the mean ± S.D. (n = 10). The (*) denotes statistically signiﬁcantfrom the type of surfactant, the surface charge of NP was identiﬁed as
another factor inﬂuencing the γmin, where PS100− showed increased
inactivation potency compared to PS100+.
4. Discussion
4.1. NP characteristics
Inhalative drug delivery has gained considerable attraction for the
treatment of numerous lung diseases [51]. In general, the advantages
of inhalation therapy depend on the fate of the delivered medication
(mechanism and rate of elimination) in the respiratory tract. To over-
come the short-comings of “conventional” inhalation therapy (i.e.
rapid decay of pulmonary drug concentration), more sophisticated
pulmonary drug delivery systems, which provide controlled and
targeted drug release within the lung, need to be introduced [1].
Among them, polymeric NP reveal several advantages for the treatment
of respiratory diseases, like drug release in a predeterminedmanner and
targeting of speciﬁc sites or cell populations [2–6]. Consequently, the
number of necessary daily inhalation maneuvers and undesirable side
effects will be reduced, which in turnwill clearly improve the therapeu-
tic beneﬁt as well as the convenience and compliance of patients.
Model formulations (i.e. PS100− and PS100+) exhibited physico-
chemical characteristics similar to frequently lung-delivered polymeric
nanocarriers [2–6] with respect to size (i.e. ~100 nm) and surface
chemistry (i.e. negative and positive surface charge) (Fig. 1, Table 1).
As expected, no surface activity was obtained for the solvent and two
polymeric NP formulations when tested in the PBS (Table 1) [33,52].
4.2. Characteristics of surfactant preparations
Pulmonary surfactant is an essential element of the terminal air-
spaces [15,20]. The surface-active lining material stabilizes the respira-
tory region by reducing the surface tension, thereby facilitating the gas-
eous exchange. Numerous studies have addressed the impact of
composition and complex interaction of surfactant constituents that en-
able rapid adsorption and a decrease in surface tension to values near
0 mN/m during compression/expansion cycles [19,53]. It is evident
that both PL and hydrophobic SP (i.e. SP-B and SP-C) are mandatory
for adequate surfactant function in the lung [19–22]. Single PLM,
which depicts only an approximation of pulmonary surfactant PL
[43,45], displayed limited efﬁcacy in lowering the surface tension to
appropriate values (Table 2). By contrast, supplementation of synthetic
PLM with hydrophobic SP (i.e. PLM-B and Venticute®) led to rapid
adsorption (γads b 30 mN/m) and near-zero minimal surface tension
(γmin b 3 mN/m) under pulsation. LSA represent the predominant
fraction of natural lung surfactant, which are assumed to be the precur-
sor of the alveolar surfactant ﬁlm [39,40]. Depletion of hydrophilic
surfactant constituents by organic BALF extraction, as employed for
the preparation of Alveofact®, resulted in a pulmonary surfactant
preparation highly enriched in PL and hydrophobic SP [45–47,50]. As ats.
Miscellaneous (wt.%) γadsb / mN/m γminb / mN/m
PA (9.0) 54.0 ± 8.9 17.3 ± 3.9
PA (7.2) 27.2 ± 2.6* 2.8 ± 1.0*
PA (4.5)a
CaCl2 (2.5)a
26.1 ± 1.8* 2.7 ± 1.3*
Fatty acidsa
Cholesterola
25.7 ± 1.0* 3.0 ± 1.5*
Fatty acidsa
Cholesterola
25.3 ± 1.4* 2.5 ± 1.2*
differences compared to the surface properties of the PLM.
Fig. 2. Dose-related effect of PS100− (open bars) and PS100+ (closed bars) on γads of the PLM (A), PLM-B (B), Venticute® (C), Alveofact® (D), and LSA isolated from rabbit BALF (E).
Values are presented as the mean ± S.D. (n ≥ 4). Statistically signiﬁcant differences (p b 0.05): (*) surfactant preparations incubated with NP vs. blank surfactant preparations
(Table 2); (&) PLM-B vs. Venticute®; (#) Alveofact and LSA vs. all synthetic surfactant preparations; (§) LSA vs. all other surfactants; (†) PS100+ vs. PS100−.
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revealed biophysical activities comparable to those obtained for SP-
enriched PLM, which are all consistent with results measured in vivo
[15].
4.3. Biophysical inhibition of surfactant preparations by polymeric NP
A basic concern in the ﬁeld of nanomedicine is the development of
safe drug delivery vehicles causing negligible adverse effects on the bi-
ological environment present at the target site [7,54]. However, the
same properties that make polymeric NP attractive as drug delivery ve-
hicles evoked toxicity concerns after pulmonary application [9–13]. Fol-
lowing deposition in the respiratory region of the lung, NP get in direct
contact with the pulmonary surfactant interface, leading to potential
biophysical interactions that could have biocompatible or bioadverse
outcomes [14,17]. An insistent problem in the development of surfac-
tant compatible NP formulations is the lack of studies, which address
the extent and mechanisms of NP–surfactant interactions. However,
probing these interactions would facilitate the development of predic-
tive structure–activity relationships between the applied formulation
and the pulmonary environment [55].
In the current study, polymeric NP (i.e. PS100− and PS100+)
caused a dose-dependent effect on the biophysical properties of all in-
vestigated pulmonary surfactants. Although the adsorption (γads) anddynamic surface tension lowering (γmin) facilities were not adversely
affected by “low” doses of polymeric NP (i.e. b0.7 mg/ml), dose escala-
tions led to distinct surfactant inhibition (Figs. 2 and 3). Thus, the total
NP concentration appears to be an important parameter for actual sur-
factant inhibition. NP concentrations that were shown to be effective
in vitro are on the upper end of what will be reached in vivo after a sin-
gle inhalative administration. However, accumulation of polymeric NP
might be observed when frequent dosing is necessary (e.g. chronic dis-
eases), which would worsen the NP/surfactant balance. Furthermore,
the sensitivity of the diverse preparations was signiﬁcantly affected by
the surface charge (ζ-potential) of the polymeric NP. Accordingly, the
ability to inhibit the surface activity was more pronounced for
negatively-charged NP (i.e. PS100−) than for their positively-charged
counterparts (i.e. PS100+). These ﬁndings are in general agreement
with a previous study, where NP properties (e.g. surface charge) as
well as their concentration impacted the biophysical performance of
the pulmonary surfactant system [33]. Surfactant dysfunction provoked
by nano-scale particulate matter occurs through a direct interaction
with individual surfactant constituents (e.g. SP) [23,25,26,33]. In these
studies, the ability of NP to adsorb the hydrophobic, positively-
charged SP (i.e. SP-B and SP-C) was offered as a putative mechanism
for the altered surfactant function. Moreover, adsorption of hydrophilic
SP (e.g. SP-A) tometal and polymeric NPwas shown to trigger their up-
take by alveolar macrophages [17,56–58]. Protein adsorption processes
Fig. 3.Dose-related effect of PS100− (open symbols) and PS100+ (closed symbols) onγmin of the PLM (A), PLM-B (B), Venticute® (C), Alveofact® (D), and LSA isolated from rabbit BALF
(E). Values are presented as the mean ± S.D. (n ≥ 4). The continuous lines in (A)–(E) represent sigmoidal dose-response ﬁts of the experimental data (R2 ≥ 0.93).
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hydrophobic and Coulomb forces [33,59]. Therefore, SP-B and SP-C
should reveal different afﬁnity to the surfaces of both NP types, presum-
ing a favored electrostatic interaction with PS100− compared to
PS100+, as indirectly documented by the impact of these formulations
on surfactant function (Figs. 2, 3 and 4, Table 3).
The type of pulmonary surfactant preparation was identiﬁed as
another determinant for the extent of NP-conditioned surfactant inhibi-
tion. It is well known that the composition of pulmonary surfactants
strongly inﬂuences their structural properties (i.e. ultrastructure)
[47,60,61], interfacial behavior (i.e. surface tension and viscosity)
[47,50,60] and sensitivity to biophysical inhibition [15]. As an example,
the sensitivity of pulmonary surfactants to biophysical inhibition by
plasma proteins (e.g. ﬁbrinogen) was shown to correlate with surfac-
tant constitution, where synthetic PLM and PLM with added rSP-C
were the most sensitive preparations, PLM-B and naturally-derived
preparations being the least [15,46,62,63]. Similar results were made
in the current study (Figs. 2, 3 and 4, Table 3). Here, the employed
PLMwas very sensitive to inhibition by polymeric NP. Supplementation
with SP-B (i.e. PLM-B) or rSP-C (i.e. Venticute®) partly shifted the
sensitivity of the PLM. However, Venticute® displayedmarkedly higher
susceptibility to inactivation than PLM-B. In contrast, when naturally-
derived pulmonary surfactants were applied a signiﬁcantly decreased
sensitivity to inhibition by polymeric NP was noticed. Several aspects
may predetermine the rank order of surfactant sensitivity toNP-conditioned biophysical inhibition, most likely variations in the PL
proﬁle and SP nature and content [15,16]. Moreover, the more complex
surfactant preparations (including for instance SP-A) reveal a higher
level of aggregation and membrane–membrane contacts, which could
prevent accessibility of polymeric NP to interact with the “delicate” con-
stituents of the surface activity “machinery”, in a similarmanner to how
those preparations are also the more resistant to other inhibitory sub-
stances. Overall, our ﬁndings and speculations prompt further investi-
gation on the interactions between polymeric NP and individual
surfactant components (i.e. PL and SP) and the effect of polymeric NP
on the (ultra)structure of pulmonary surfactant preparations to fully ex-
plain the physiological relevance of adsorption and dynamic surface
tension alterations.
5. Conclusion
Controlled drug release and targeting properties are prerequisites
for the fabrication of suitable polymeric nanocarriers for lung adminis-
tration. However, nano-scale particulate matter was shown to interact
with the essential pulmonary surfactant system. Consequently, relevant
carrier characteristics need to be identiﬁed, which enable the fabrica-
tion of surfactant-compatible polymeric NP formulations. In this regard,
the current study underlined the signiﬁcance of NP characteristics (i.e.
surface charge) and surfactant composition on the extent of biophysical
inhibition. The ability of polymeric NP to adsorb SP was regarded as a
Fig. 4. Calculated dose-effect curve characteristics for biophysical inhibition experiments
(PS100− (open bars) and PS100+ (closed bars)). Values were obtained from sigmoidal
dose-response ﬁts displayed in Fig. 3 and are presented as the mean ± S.D. (n ≥ 4).
Statistically signiﬁcant differences (p b 0.05): (*) all surfactant preparations vs. PLM;
(&) PLM-B vs. Venticute®; (#) Alveofact and LSA vs. all synthetic surfactant preparations;
(§) LSA vs. all other surfactants; (†) PS100+ vs. PS100−.
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Surface characteristics of the NP were shown to contribute actively to
interactions with the biological environment. The overall stability of
the employed pulmonary surfactants towards biophysical inhibition
by polymeric NP was also dependent on preparation origin and compo-
sition and could be ranked in the following order: PLM b Venticute®
b PLM-B b Alveofact® b LSA. Overall, the ﬁndings from the current
study represent a basis for the rational design of nanomedicines suitable
for pulmonary drug delivery applications.Conﬂict of interest
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